A new Phase 3 clinical research study is now open at OSF HealthCare Cancer Institute for adults with ovarian, fallopian tube, or primary peritoneal cancer. The study is evaluating an investigational targeted therapy, sofetabart mipitecan, in people whose cancer is either platinum-resistant or platinum-sensitive.

This study is testing a new kind of targeted medicine for women with advanced ovarian cancer. The investigational drug uses an antibody to locate cancer cells with the FRα protein on their surface and then delivers treatment directly to those cells. Researchers are studying whether this approach is safe and whether it can help control the cancer better than current standard options.

Sofetabart mipitecan (ClinicalTrials.gov Identifier: NCT07213804) is being studied in FRAmework-01, a global, three-part Phase 3 trial. The investigational medicine is an antibody-drug conjugate designed to find cancer cells that express a protein called folate receptor alpha (FRα) and then deliver an anti-cancer agent directly to those cells. In one part of the study, the investigational therapy is compared with standard chemotherapy or another approved targeted treatment. In other parts, it is studied in combination with bevacizumab and compared with platinum-based chemotherapy plus bevacizumab. At OSF HealthCare, the study is being led by Principal Investigator Michelle Rowland, MD, PhD, MPH, with Clinical Research Coordinator Lisa Gale.

This research is meaningful for patients and our community because ovarian cancer that returns after platinum-based chemotherapy remains very difficult to treat, and many patients have limited options. Studies like this help evaluate new targeted approaches under careful medical supervision and bring investigational therapies closer to those who need them most. Support for clinical research through OSF HealthCare allows us to offer hope and help advance care for future generations.

“OSF HealthCare is deeply committed to advancing care for patients with gynecologic malignancies, including the significant challenges of platinum-resistant and platinum-sensitive ovarian cancer,” said Michelle Rowland, MD, PhD, MPH, Principal Investigator at OSF HealthCare Cancer Institute. “Clinical trials like this one offer eligible patients the opportunity to receive promising investigational therapies under close medical supervision, while helping generate high-quality data that can improve treatment approaches for future patients.”

All treatment approaches in this study are being evaluated for research purposes in accordance with the approved study protocol.

All clinical research conducted at OSF HealthCare undergoes rigorous review and ongoing oversight to help ensure patient safety and ethical conduct.

Patients interested in learning more about clinical research at OSF HealthCare are encouraged to speak with their care team, call (844) 673-4467 or Email: sfmc.clinicaltrials@osfhealthcare.org